This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shibutani, S. Articles by Sancar, A. Search for Related Content PubMed PubMed Citation Articles by Shibutani, S. Articles by Sancar, A.

Excision of Tamoxifen-DNA Adducts by the Human Nucleotide Excision Repair System¹

Department of Pharmacological Sciences, State University of New York at Stony Brook, Stony Brook, New York 11794 [S. S., N. S.], and Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599 [J. T. R., A. S.]

The antiestrogen tamoxifen is used in the treatment of breast cancer and has recently been recommended as a chemopreventive drug for women at high risk for breast cancer. However, women treated with the drug have an increased incidence of endometrial cancer. It has been suggested that this endometrial cancer might result from mutagenic DNA adducts, which are formed by electrophilic tamoxifen species generated by metabolic activation of the drug. Because the frequency of damage-induced mutations is strongly dependent on the repairability of the lesion, we investigated the repair of the major tamoxifen-DNA adducts by the human nucleotide excision repair system. Using the reconstituted human excision repair system and synthetic DNA substrates, we found that the four types of tamoxifen-DNA adducts detected in the endometrium were repaired with moderate to poor efficiency by nucleotide excision repair. It is concluded that individual variations in repair capacity may play a role in the development of tamoxifen-induced endometrial cancer.

This article has been cited by other articles:

				K. Brown Is tamoxifen a genotoxic carcinogen in women? Mutagenesis, September 1, 2009; 24(5): 391 - 404. [Abstract] [Full Text] [PDF]

				K. I. E. McLuckie, J. H. Lamb, J. K. Sandhu, H. L. Pearson, K. Brown, P. B. Farmer, and D. J. L. Jones Development of a novel site-specific mutagenesis assay using MALDI-ToF MS (SSMA-MS) Nucleic Acids Res., December 6, 2006; (2006) gkl745v2. [Abstract] [Full Text] [PDF]

				S. Y. Kim, N. Suzuki, Y. R. S. Laxmi, and S. Shibutani INEFFICIENT REPAIR OF TAMOXIFEN-DNA ADDUCTS IN RATS AND MICE Drug Metab. Dispos., February 1, 2006; 34(2): 311 - 317. [Abstract] [Full Text] [PDF]

				R. A. Sharma and P. B. Farmer Biological Relevance of Adduct Detection to the Chemoprevention of Cancer Clin. Cancer Res., August 1, 2004; 10(15): 4901 - 4912. [Abstract] [Full Text] [PDF]

				M.E. Heres-Pulido, I. Duenas-Garcia, L. Castaneda-Partida, A. Sanchez-Garcia, M. Contreras-Sousa, A. Duran-Diaz, and U. Graf Genotoxicity of tamoxifen citrate and 4-nitroquinoline-1-oxide in the wing spot test of Drosophila melanogaster Mutagenesis, May 1, 2004; 19(3): 187 - 193. [Abstract] [Full Text] [PDF]

				A. Mizutani, T. Okada, S. Shibutani, E. Sonoda, H. Hochegger, C. Nishigori, Y. Miyachi, S. Takeda, and M. Yamazoe Extensive Chromosomal Breaks Are Induced by Tamoxifen and Estrogen in DNA Repair-Deficient Cells Cancer Res., May 1, 2004; 64(9): 3144 - 3147. [Abstract] [Full Text] [PDF]

				S. Shibutani, N. Suzuki, Y. R. S. Laxmi, L. J. Schild, R. L. Divi, A. P. Grollman, and M. C. Poirier Identification of Tamoxifen-DNA Adducts in Monkeys Treated with Tamoxifen Cancer Res., August 1, 2003; 63(15): 4402 - 4406. [Abstract] [Full Text] [PDF]

				M. Yadollahi-Farsani, D. S. Davies, and A. R. Boobis The mutational signature of {alpha}-hydroxytamoxifen at Hprt locus in Chinese hamster cells Carcinogenesis, November 1, 2002; 23(11): 1947 - 1952. [Abstract] [Full Text] [PDF]

				D. H. Phillips Understanding the genotoxicity of tamoxifen? Carcinogenesis, June 1, 2001; 22(6): 839 - 849. [Abstract] [Full Text] [PDF]

				S. Shibutani, A. Ravindernath, I. Terashima, N. Suzuki, Y. R. Santosh Laxmi, Y. Kanno, M. Suzuki, T. I. Apak, J. J. Sheng, and M. W. Duffel Mechanism of Lower Genotoxicity of Toremifene Compared with Tamoxifen Cancer Res., May 1, 2001; 61(10): 3925 - 3931. [Abstract] [Full Text]

				J. L. Torino, M. S. Burger, C. A. Reznikoff, and S. Swaminathan Role of TP53 in repair of N-(deoxyguanosin-8-yl)-4-aminobiphenyl adducts in human transitional cell carcinoma of the urinary bladder Carcinogenesis, January 1, 2001; 22(1): 147 - 154. [Abstract] [Full Text] [PDF]